JP2010504343A5 - - Google Patents

Download PDF

Info

Publication number
JP2010504343A5
JP2010504343A5 JP2009529307A JP2009529307A JP2010504343A5 JP 2010504343 A5 JP2010504343 A5 JP 2010504343A5 JP 2009529307 A JP2009529307 A JP 2009529307A JP 2009529307 A JP2009529307 A JP 2009529307A JP 2010504343 A5 JP2010504343 A5 JP 2010504343A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
methoxymethyl
dimethylamino
der
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009529307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504343A (ja
JP5184536B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/078352 external-priority patent/WO2008036541A1/en
Publication of JP2010504343A publication Critical patent/JP2010504343A/ja
Publication of JP2010504343A5 publication Critical patent/JP2010504343A5/ja
Application granted granted Critical
Publication of JP5184536B2 publication Critical patent/JP5184536B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009529307A 2006-09-20 2007-09-13 チオフェンピラゾロピリミジン化合物 Expired - Fee Related JP5184536B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82627306P 2006-09-20 2006-09-20
US60/826,273 2006-09-20
PCT/US2007/078352 WO2008036541A1 (en) 2006-09-20 2007-09-13 Thiophene pyrazolopyrimidine compounds

Publications (3)

Publication Number Publication Date
JP2010504343A JP2010504343A (ja) 2010-02-12
JP2010504343A5 true JP2010504343A5 (US20070167479A1-20070719-C00034.png) 2010-11-04
JP5184536B2 JP5184536B2 (ja) 2013-04-17

Family

ID=38988344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529307A Expired - Fee Related JP5184536B2 (ja) 2006-09-20 2007-09-13 チオフェンピラゾロピリミジン化合物

Country Status (12)

Country Link
US (1) US8110580B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2076515B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP5184536B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR101088196B1 (US20070167479A1-20070719-C00034.png)
CN (1) CN101516886B (US20070167479A1-20070719-C00034.png)
AU (1) AU2007297481B2 (US20070167479A1-20070719-C00034.png)
BR (1) BRPI0717070A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2662000C (US20070167479A1-20070719-C00034.png)
EA (1) EA016056B1 (US20070167479A1-20070719-C00034.png)
ES (1) ES2428543T3 (US20070167479A1-20070719-C00034.png)
MX (1) MX2009003098A (US20070167479A1-20070719-C00034.png)
WO (1) WO2008036541A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ, インコーポレイテッド チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
NZ607087A (en) 2010-08-11 2015-05-29 Millennium Pharm Inc Heteroaryls as inhibitors of pi3k and for the treatment of proliferative, inflammatory, or cardiovascular disorders
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG189396A1 (en) 2010-10-13 2013-05-31 Millennium Pharm Inc Heteroaryls and uses thereof
ES2606043T3 (es) 2011-07-05 2017-03-17 Lupin Limited Derivados de biarilo como moduladores de nAChR
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2015209452C1 (en) 2014-01-21 2020-11-05 Neurocrine Biosciences, Inc. CRF1 receptor antagonists for the treatment of congenital adrenal hyperplasia
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
EP3238676B1 (en) 2016-04-29 2019-01-02 The Procter and Gamble Company Absorbent core with profiled distribution of absorbent material
KR102644781B1 (ko) * 2017-08-14 2024-03-06 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
AR120649A1 (es) * 2019-12-04 2022-03-09 Neurocrine Biosciences Inc Antagonistas del receptor de crf y métodos de uso
BR112023002497A2 (pt) 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2895961B2 (ja) 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Crfアンタゴニストとしてのピロロピリミジン
IL123835A0 (en) * 1996-02-07 1998-10-30 Janssen Pharmaceutica Nv Pyrazolopyrimidines as CRF receptor antagonists
WO1998003510A1 (en) 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company AZOLO TRIAZINES AND PYRIMIDINES
ES2273369T3 (es) 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
CA2379633C (en) * 1999-09-30 2006-06-20 Neurogen Corporation Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
NZ547990A (en) * 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto
BRPI0608857A2 (pt) * 2005-03-21 2012-08-28 Lilly Co Eli composto, e, composição farmacêutica

Similar Documents

Publication Publication Date Title
JP2010504343A5 (US20070167479A1-20070719-C00034.png)
JP2012502037A5 (US20070167479A1-20070719-C00034.png)
JP2007145875A5 (US20070167479A1-20070719-C00034.png)
JP2013542247A5 (US20070167479A1-20070719-C00034.png)
JP2010526814A5 (US20070167479A1-20070719-C00034.png)
JP2009502743A5 (US20070167479A1-20070719-C00034.png)
JP2010530897A5 (US20070167479A1-20070719-C00034.png)
JP2010521514A5 (US20070167479A1-20070719-C00034.png)
JP2010536766A5 (US20070167479A1-20070719-C00034.png)
JP2013518107A5 (US20070167479A1-20070719-C00034.png)
JP2006526031A5 (US20070167479A1-20070719-C00034.png)
JP2010077141A5 (US20070167479A1-20070719-C00034.png)
JP2009507896A5 (US20070167479A1-20070719-C00034.png)
JP2013510123A5 (US20070167479A1-20070719-C00034.png)
JP2014515013A5 (US20070167479A1-20070719-C00034.png)
JP2007302689A5 (US20070167479A1-20070719-C00034.png)
JP2010536889A5 (US20070167479A1-20070719-C00034.png)
JP2010501478A5 (US20070167479A1-20070719-C00034.png)
JP2014500861A5 (US20070167479A1-20070719-C00034.png)
JP2011519854A5 (US20070167479A1-20070719-C00034.png)
JP2010502730A5 (US20070167479A1-20070719-C00034.png)
JP2011518833A5 (US20070167479A1-20070719-C00034.png)
JP2013509429A5 (US20070167479A1-20070719-C00034.png)
JP2011528658A5 (US20070167479A1-20070719-C00034.png)
JP2006524660A5 (US20070167479A1-20070719-C00034.png)